| Year |
Citation |
Score |
| 2014 |
LaFave MC, Andersen SL, Stoffregen EP, Holsclaw JK, Kohl KP, Overton LJ, Sekelsky J. Sources and structures of mitotic crossovers that arise when BLM helicase is absent in Drosophila. Genetics. 196: 107-18. PMID 24172129 DOI: 10.1534/genetics.113.158618 |
0.52 |
|
| 2011 |
Stoffregen EP, Donley N, Stauffer D, Smith L, Thayer MJ. An autosomal locus that controls chromosomewide replication timing and mono-allelic expression Human Molecular Genetics. 20: 2366-2378. PMID 21459774 DOI: 10.1093/hmg/ddr138 |
0.52 |
|
| 2008 |
Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 111: 4788-96. PMID 18252861 DOI: 10.1182/blood-2007-07-101394 |
0.52 |
|
| 2006 |
Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Molecular and Cellular Biology. 26: 6082-6093. PMID 16880519 DOI: 10.1128/MCB.02202-05 |
0.52 |
|
| 2006 |
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10: 65-75. PMID 16843266 DOI: 10.1016/j.ccr.2006.06.002 |
0.52 |
|
| 2006 |
Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leukemia Research. 30: 1097-104. PMID 16464493 DOI: 10.1016/j.leukres.2006.01.001 |
0.52 |
|
| 2005 |
O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6987-93. PMID 16203792 DOI: 10.1158/1078-0432.CCR-05-0622 |
0.52 |
|
| 2005 |
Crossman LC, O'Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O'Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MWN. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib Leukemia. 19: 1859-1862. PMID 16151465 DOI: 10.1038/sj.leu.2403935 |
0.52 |
|
| 2005 |
Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 106: 3377-9. PMID 16081687 DOI: 10.1182/blood-2005-05-1898 |
0.52 |
|
| 2005 |
O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research. 65: 4500-5. PMID 15930265 DOI: 10.1158/0008-5472.CAN-05-0259 |
0.52 |
|
| 2005 |
Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 106: 2128-37. PMID 15914554 DOI: 10.1182/blood-2005-03-1036 |
0.52 |
|
| 2005 |
Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood. 105: 2952-4. PMID 15585651 DOI: 10.1182/blood-2004-07-2758 |
0.52 |
|
| 2004 |
O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 104: 2532-9. PMID 15256422 DOI: 10.1182/blood-2004-05-1851 |
0.52 |
|
| Show low-probability matches. |